Vasopressin receptor antagonist use in a neurologic rehabilitation center.
OBJECTIVE
To report successful use of a modified protocol of vasopressin receptor antagonist for effective and safe treatment of hyponatremia in a complexly ill patient in the neurorehabilitation setting.


METHODS
Case report.


METHODS
A 57-year-old man with tetraparesis and protracted hyponatremia resistant to standard therapies.


RESULTS
This patient's rehabilitation from epidural abscess-induced tetraplegia was complicated by symptomatic hyponatremia. The pathophysiology was multifactorial. The course was prolonged, and several therapeutic endeavors failed. Intravenous infusions of vasopressin receptor antagonist induced and maintained eunatremia. The pace of the patient's recovery improved, and he was discharged with substantial neurologic recovery. No central nervous system toxicities of the treatments were observed.


CONCLUSIONS
Intravenous vasopressin receptor antagonist is an effective and safe treatment for hyponatremia in the rehabilitation setting if the dosage and monitoring protocols are modified in accordance with the physiology of the patient with spinal cord injury.
Garrett
Raymond E
RE
Trauma Research Department, Swedish Medical Center, 501 E. Hampden Avenue, Room 4-454, Englewood, CO 80113, USA. docraynjoy@aol.com
Wilhelm
Stacia
S
Maerz
Gary
G
Bar-Or
David
D
D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000627:therapeutic use*; D006801:Humans; D007010:Hyponatremia / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011782:Quadriplegia / Q000150:complications / Q000188:drug therapy*; D016320:Substance Abuse Treatment Centers
D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; C106389:conivaptan
Am J Med Sci. 2007 Feb;333(2):101-5
17301588
Am J Med Sci. 2002 May;323(5):259-62
12018668
Am J Med Sci. 2000 Apr;319(4):240-4
10768609
J Clin Endocrinol Metab. 2006 Jun;91(6):2145-52
16522696
Nephron. 2002;92 Suppl 1:9-13
12401932
Am J Med. 2007 Nov;120(11 Suppl 1):S1-21
17981159